Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The need to stem the current outbreak of SARS-CoV-2 responsible for COVID-19 is driving the search for inhibitors that will block coronavirus replication and pathogenesis. The coronavirus 3C-like protease (3CLpro) encoded in the replicase polyprotein is an attractive target for antiviral drug development because protease activity is required for generating a functional replication complex. Reagents that can be used to screen for protease inhibitors and for identifying the replicase products of SARS-CoV-2 are urgently needed. Here we describe a luminescence-based biosensor assay for evaluating small molecule inhibitors of SARS-CoV-2 3CLpro/main protease. We also document that a polyclonal rabbit antiserum developed against SARS-CoV 3CLpro cross reacts with the highly conserved 3CLpro of SARS-CoV-2. These reagents will facilitate the pre-clinical evaluation of SARS-CoV-2 protease inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837110 | PMC |
| http://dx.doi.org/10.1016/j.virol.2021.01.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protein-losing enteropathy in a paediatric patient with Kawasaki disease: a rare clinical manifestation.
BMJ Case Rep
September 2025
Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Kawasaki disease (KD) is an acute vasculitis of childhood, which can lead to complications affecting multiple organ systems. Protein-losing enteropathy (PLE) is an extremely rare complication of KD, characterised by excessive protein loss through the gastrointestinal tract, leading to hypoalbuminaemia, oedema and immune dysfunction. We report a case of an early childhood boy with intravenous immune globulin (IVIG)-resistant incomplete KD who developed PLE.
View Article and Find Full Text PDF[Sex differences in the pharmacological treatment of hypertension in primary care].
Ned Tijdschr Geneeskd
September 2025
UMC Utrecht, afd. huisartsgeneeskunde, Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde, Utrecht.
Objective: To investigate sex differences in the pharmacological treatment of hypertension in primary care.
Design: Cross-sectional study among 14,384 patients with hypertension from the Julius General Practitioners' Network, without cardiovascular disease or diabetes, treated with antihypertensive medications.
Methods: We compared men and women in the number and type of prescribed antihypertensives and their blood pressure.
Aim Search for subclinical manifestations of cardiotoxicity in cancer patients at high and very high risk of cardiotoxicity and evaluation of the effectiveness of drug primary prevention during the antitumor treatment. Material and methods The study included 150 cancer patients with a high and very high Mayo Clinic (USA) Cardiotoxicity Risk Score. The main group consisted of 84 patients at high and very high risk of cardiotoxicity who were prescribed cardioprotective therapy, including a fixed combination of the angiotensin-converting enzyme inhibitor (ACEI) perindopril and the beta-blocker bisoprolol with trimetazidine.
View Article and Find Full Text PDFThe manipulator behind "Scissors": γ -secretase and its modulators in Alzheimer's disease.
Front Aging Neurosci
August 2025
Yan'an Medical College of Yan'an University, Yan'an, Shaanxi, China.
The intramembrane aspartic protease, γ-secretase, is a heterotetrameric protein complex composed of four integral membrane proteins: presenilin (PSEN), nicastrin (NCT), Anterior pharynx defective-1 (APH-1), and presenilin enhancer 2 (PEN-2). These components are sequentially assembled into a functional complex. γ-secretase is ubiquitously expressed in all cells and tissues and exhibits enzymatic activity akin to "molecular scissors" by cleaving various type I transmembrane proteins.
View Article and Find Full Text PDFBackgroundRAY1216 is an alpha-ketoamide-based peptide inhibitor of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) major protease (M). This study evaluated the absorption, distribution, metabolism and excretion of [C]-labelled RAY1216 by oral administration.Research design and methodsThis phase Ι study was designed to assess the pharmacokinetics, mass balance and metabolic pathways in 6 healthy Chinese adult men after a single fasting oral administration of 240 mL (containing 400 mg/100 μCi) [C] RAY1216.
View Article and Find Full Text PDF